Start Up Costs Only Account: 24-MULTI-66-TB-PMC (TORL4500-001): A Phase 1, First in Human Study of TORL-4-500 in Patients with Advanced Cancer

Human Clinical - Confidential. Name of lnvestigational Product: TORL-4-500 Name of Active Ingredient: TORL-4-500 Protocol Number: Phase: 1 Country: United TORL4500-001 States, Canada Title of Study: A Phase 1, First in Human Study ofTORL-4-500 in Patients with Advanced Cancer Studied period (years): Phase of development: 1 Estimated date first patient enrolled: 31 OCT 2023 Estimated date last patient completed: 31 OCT 2027 Objectives and Endpoints: Primary Objective: Endpoint/Variable: To characterize the safety, tolerability, and DLT Safety: AEs/SAEs; Changes in clinical and to determine the MTD and the RP2D of laboratory values TORL-4-500 administered as monotherapy in patients with advanced cancer.